Newland Pharmaceutical Co., Ltd. (SHE:301277)
China · Delayed Price · Currency is CNY 10.10
-0.20 (-1.94%)
Sep 9, 2026, 4:00 PM EDT
Newland Pharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 158 | 169 | 281.58 | 270.02 | 51.13 | 34.21 |
Trading Asset Securities | 460.62 | 549.55 | 525.16 | 589.5 | 701.36 | 8.67 |
Cash & Short-Term Investments | 618.62 | 718.55 | 806.75 | 859.52 | 752.49 | 42.88 |
Cash Growth | -6.38% | -10.93% | -6.14% | 14.22% | 1654.94% | 17.63% |
Accounts Receivable | 333.54 | 270.55 | 332.61 | 240.9 | 360.46 | 269.6 |
Other Receivables | 0.27 | 0.03 | 0.06 | 0.19 | 0.26 | 0.16 |
Receivables | 333.81 | 270.58 | 332.67 | 241.09 | 360.72 | 269.76 |
Inventory | 88.05 | 72.37 | 45.06 | 31 | 53.52 | 78.57 |
Other Current Assets | 5.53 | 5.18 | 10.55 | 25.04 | 20.38 | 9.8 |
Total Current Assets | 1,046 | 1,067 | 1,195 | 1,157 | 1,187 | 401 |
Property, Plant & Equipment | 641 | 659.65 | 574.78 | 388.2 | 295.52 | 225.67 |
Long-Term Investments | 14.88 | - | - | - | - | - |
Other Intangible Assets | 49.05 | 49.99 | 36.82 | 38.08 | 38.77 | 39.71 |
Long-Term Deferred Tax Assets | - | - | - | - | - | 1.01 |
Long-Term Deferred Charges | 0.61 | 1.34 | 3.38 | 5.61 | 1.29 | - |
Other Long-Term Assets | 2.87 | 1.85 | 3.73 | 20.96 | 11.08 | 0.51 |
Total Assets | 1,754 | 1,780 | 1,814 | 1,610 | 1,534 | 667.9 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 108.87 | 97.68 | 138.66 | 87.75 | 106.37 | 80.26 |
Accrued Expenses | 15.56 | 24.37 | 23.78 | 30.33 | 18.18 | 27.81 |
Short-Term Debt | 0.47 | - | 0.73 | - | - | 91.33 |
Current Portion of Long-Term Debt | 2.19 | - | - | - | - | 4.66 |
Current Portion of Leases | - | 2.81 | - | 1.99 | 2.84 | - |
Current Income Taxes Payable | 4.95 | 0.06 | - | - | - | 3.05 |
Current Unearned Revenue | 2.46 | 3.28 | 5.32 | 4.43 | 4.61 | 1.68 |
Other Current Liabilities | 25.94 | 42.17 | 48.3 | 14.96 | 24.01 | 11.8 |
Total Current Liabilities | 160.45 | 170.35 | 216.78 | 139.47 | 156.01 | 220.58 |
Long-Term Debt | - | - | - | - | - | 30.39 |
Long-Term Leases | 1.55 | 2.89 | 2.25 | 0.73 | 2.88 | - |
Long-Term Unearned Revenue | 49.13 | 44.23 | 41.88 | 10.04 | 10.3 | 10.56 |
Long-Term Deferred Tax Liabilities | 10.57 | 11.02 | 9.77 | 9.78 | 5.39 | - |
Total Liabilities | 221.7 | 228.49 | 270.69 | 160.02 | 174.58 | 261.53 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 392.08 | 392.08 | 280.06 | 200.04 | 133.36 | 100 |
Additional Paid-In Capital | 532.74 | 532.74 | 644.77 | 724.78 | 791.46 | 5.49 |
Retained Earnings | 602.28 | 619.93 | 610.7 | 517.09 | 424.79 | 292.48 |
Comprehensive Income & Other | 6.62 | 6.59 | 6.67 | 6.11 | 6.33 | 4.56 |
Total Common Equity | 1,534 | 1,551 | 1,542 | 1,448 | 1,356 | 402.53 |
Minority Interest | -1.01 | -0.33 | 0.85 | 1.47 | 3.25 | 3.85 |
Shareholders' Equity | 1,533 | 1,551 | 1,543 | 1,449 | 1,359 | 406.38 |
Total Liabilities & Equity | 1,754 | 1,780 | 1,814 | 1,610 | 1,534 | 667.9 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 4.22 | 5.69 | 2.98 | 2.72 | 5.72 | 126.38 |
Net Cash (Debt) | 614.4 | 712.86 | 803.77 | 856.8 | 746.77 | -83.5 |
Net Cash Growth | -6.09% | -11.31% | -6.19% | 14.73% | - | - |
Net Cash Per Share | 1.56 | 1.82 | 2.04 | 2.19 | 2.48 | -0.28 |
Filing Date Shares Outstanding | 392.12 | 392.08 | 392.08 | 392.08 | 392.08 | 294 |
Total Common Shares Outstanding | 392.12 | 392.08 | 392.08 | 392.08 | 392.08 | 294 |
Working Capital | 885.55 | 896.33 | 978.24 | 1,017 | 1,031 | 180.43 |
Book Value Per Share | 3.91 | 3.96 | 3.93 | 3.69 | 3.46 | 1.37 |
Tangible Book Value | 1,485 | 1,501 | 1,505 | 1,410 | 1,317 | 362.82 |
Tangible Book Value Per Share | 3.79 | 3.83 | 3.84 | 3.60 | 3.36 | 1.23 |
Buildings | - | 380.5 | 211.94 | 169.21 | 151.69 | 148.36 |
Machinery | - | 467.7 | 295.69 | 235.66 | 187.31 | 125.82 |
Construction In Progress | - | 13.46 | 222.1 | 106.7 | 55.35 | 33.02 |